10% original issue discount 5% Senior Convertible NOTE DUE NOVEMBER 13, 2018OncBioMune Pharmaceuticals, Inc • May 31st, 2018 • Pharmaceutical preparations • New York
THIS 10% SENIOR CONVERTIBLE NOTE is one of a series of duly authorized and validly issued 5% Senior Convertible Notes issued at a 10% original issue discount by OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”) (this note, the “Note” and, collectively with the other notes of such series, the “Notes”).
COMMON STOCK PURCHASE WARRANT OncBioMune Pharmaceuticals, Inc.OncBioMune Pharmaceuticals, Inc • May 31st, 2018 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, __________________, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five (5) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), up to ___________ shares of Common Stock (subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITY AGREEMENTSecurity Agreement • May 31st, 2018 • OncBioMune Pharmaceuticals, Inc • Pharmaceutical preparations • New York
THIS SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of January 29, 2018 between OncBioMune Pharmaceuticals, Inc., a Nevada corporation (“OBMP”) and OncBioMune, Inc., a Louisiana corporation (the “Subsidiary”) (the Subsidiary, together with each other Person who becomes a party to this Agreement by execution of a joinder in the form of Exhibit A attached hereto, which shall include all wholly-owned or majority-owned subsidiaries of OBMP acquired after the date hereof for so long as this Agreement remains in effect, are hereinafter sometimes referred to individually as a “Debtor” and, collectively, as the “Debtors”) and Cavalry Fund I LP, a Delaware limited partnership, in its capacity as Collateral Agent (subject to Section 1A, below) for the benefit of itself and each of the Purchasers (as hereinafter defined) (together with their successors and assigns, the “Secured Parties”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 31st, 2018 • OncBioMune Pharmaceuticals, Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March 13, 2018, between OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
SUBSIDIARY GUARANTYSubsidiary Guaranty • May 31st, 2018 • OncBioMune Pharmaceuticals, Inc • Pharmaceutical preparations • New York
This SUBSIDIARY GUARANTY (as amended, restated, supplemented, or otherwise modified and in effect from time to time, this “Guaranty”) is made as of this 13th day of March, 2018, jointly and severally, between OncBioMune Pharmaceuticals, Inc., a Nevada corporation (“OBMP”) and OncBioMune, Inc., a Louisiana corporation (“the “Subsidiary” and, together with OBMP, the “Companies”) (the Subsidiary together with each other person or entity who becomes a party to this Guaranty by execution of a joinder in the form of Exhibit A attached hereto, which shall include all wholly-owned or majority-owned subsidiaries of OBMP acquired after the date hereof for so long as this Guaranty remains in effect, shall each referred to individually as a “Guarantor” and collectively as the “Guarantors”); in favor of the Purchasers listed on the signature pages of that certain Securities Purchase Agreement dated March 13, 2018 (each, a “Purchaser”, and together with its successors and assigns and each other purc
PLEDGE AGREEMENTPledge Agreement • May 31st, 2018 • OncBioMune Pharmaceuticals, Inc • Pharmaceutical preparations • New York
THIS PLEDGE AGREEMENT made as of this 29th day of January, 2018 (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”), by OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Pledgor”) and Cavalry Fund I LP, a Delaware limited partnership, in its capacity as agent (subject to Section 1A, below) (“Agent”) for the Purchasers identified below (in such capacity, together with its successors and assigns, the “Pledgee”).
